Stock News•1 week ago
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
AstraZeneca's oncology sales rose 15% in H1 2026, driven by newer drugs, label expansions, and a deep pipeline, supporting continued franchise growth.
MarketLens
Why Are Institutional Giants Like Manulife Betting Big on AstraZeneca
4 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Why Are Lawmakers Betting Big on Citigroup
5 months ago
Why is eBay betting big on Depop
7 months ago
Category
You may also like
Stock News•2 weeks ago
Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?
AstraZeneca (AZN) is the subject of a media piece examining whether Wall Street's bullish analyst views justify investment, though no specific rating changes or price targets are cited. The article no...
Stock News•2 months ago
Astrazeneca Plc $AZN Shares Acquired by DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale boosted its AstraZeneca holdings by 4,529% in Q1, acquiring 3.7M additional shares. The stake now represents ~1.2% of the fund's portfolio.
Breaking News
View All →Featured Articles
Top Headlines
Stock News•1 hour ago
Microsoft (MSFT) Exceeds Market Returns: Some Facts to Consider
Stock News•1 hour ago
Nvidia (NVDA) Outperforms Broader Market: What You Need to Know
Stock News•1 hour ago
Tesla (TSLA) Laps the Stock Market: Here's Why
Stock News•1 hour ago
If you'd bought $10,000 worth of Amazon stock 10 years ago, here's how much you'd have today
Stock News•1 hour ago